Mini Oral session
Invited Discussant of abstracts 26MO and 27MO
Date
07 Mar 2022Session
Mini Oral sessionPresenters
Kapil DhingraAuthors
K. DhingraAuthor affiliations
- KAPital Consulting LLC,, New York/US
Resources
Resources from the same session
5MO - Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase
Presenter: Elisa Fontana
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
6MO - Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumors
Presenter: Wael Jdey
Session: Mini Oral session
Resources:
Abstract
Webcast
7MO - WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in small cell lung cancer
Presenter: Triparna Sen
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
26MO - Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
Presenter: Sophie Sun
Session: Mini Oral session
Resources:
Abstract
27MO - BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models.
Presenter: Matthew Lucas
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 5MO, 6MO and 7MO
Presenter: Geoffrey Shapiro
Session: Mini Oral session
Resources:
Slides
Webcast
Live Q&A and discussion
Presenter: Geoffrey Shapiro
Session: Mini Oral session
Resources:
Webcast
Live Q&A and discussion
Presenter: Geoffrey Shapiro
Session: Mini Oral session
Resources:
Webcast